Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase NA 1Phase 4 1Phase 3 1Phase 2/3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 8Wilms Tumor 1Recurrence 1Patient Acceptance of Health Care 1Non-Muscle Invasive Bladder Neoplasms 1Neoplastic Cells, Circulating 1Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Carcinoma, Hepatocellular 1

Interventions

Cyclophosphamide 4Vincristine 2selinexor 1fludarabine phosphate 1fludarabine 1axicabtagene ciloleucel 1apatinib 1VAP-cyclo protocol 1Thiotepa 1Rituximab 1Radiotherapy 1R-CHOP protocol 1Prednisone 1Nurse Clinicians 1Methotrexate 1Melphalan 1Lomustine 1Ifosfamide 1Idarubicin 1Filgrastim 1Etoposide 1Epirubicin 1Doxorubicin 1Dexamethasone 1Decitabine 1Cytarabine 1Carmustine 1Brentuximab Vedotin 1Blood Pressure 1Antiretroviral Therapy, Highly Active 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Lymphoma, Large B-Cell, Diffuse × Epirubicin × Clear all
NCT02752815 2022-12-05

Reduced Chemotherapy in Low Risk DLBCL

Ruijin Hospital

Phase 4 Unknown
290 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡